ICPT Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 lapkr. 2023 @ 23:00):

Stats
Dzisiejszy wolumen	3.91M
Średni wolumen	2.05M
Kapitalizacja rynkowa	794.69M
EPS	$0 ( 2024-04-25 )
Następna data zysków	( $0 ) 2024-07-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-17.43
ATR14	$0.410 (2.16%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-08	Akkaraju Srinivas	Sell	640 688	Common Stock
2023-11-08	Akkaraju Srinivas	Sell	8 111	Common Stock
2023-11-08	Akkaraju Srinivas	Sell	12 089	Option to Purchase Common Stock
2023-11-08	Akkaraju Srinivas	Sell	12 790	Option to Purchase Common Stock
2023-11-08	Akkaraju Srinivas	Sell	12 547	Option to Purchase Common Stock

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 1 646 020

Wolumen Korelacja

Długi: 0.26 (neutral)

Krótki: 0.00 (neutral)

Signal:(75.794) Neutral

Intercept Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
ADMS	0.992
PATI	0.988
ZGNX	0.963
RETA	0.958
RESN	0.956
TRMR	0.95
DXPE	0.948
MNMD	0.946
SG	0.945
VITL	0.943

10 Najbardziej negatywne korelacje
CPSH	-0.949
PHCF	-0.943
CDAK	-0.942
UONE	-0.942
AZYO	-0.942
TTEC	-0.941
DTEA	-0.935
UONEK	-0.932
JRJC	-0.931
OFS	-0.93

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intercept Pharmaceuticals Korelacja - Waluta/Towar

0.35
( neutral )

0.56
( weak )

-0.31
( neutral )

-0.09
( neutral )

-0.29
( neutral )

0.55
( weak )

Intercept Pharmaceuticals Finanse

Annual	2022
Przychody:	$285.71M
Zysk brutto:	$284.73M (99.66 %)
EPS:	$3.40

FY	2022
Przychody:	$285.71M
Zysk brutto:	$284.73M (99.66 %)
EPS:	$3.40

FY	2021
Przychody:	$363.47M
Zysk brutto:	$360.37M (99.15 %)
EPS:	$-2.88

FY	2020
Przychody:	$312.69M
Zysk brutto:	$307.37M (98.30 %)
EPS:	$-8.34

Financial Reports:

No articles found.

Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.